In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...
Researchers at the University of Geneva, together with colleagues in Switzerland, France, the United States and Israel, ...
Charles River Laboratories International Inc. has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP).
A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...
The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...
Aradigm Health, a new benefits platform aimed at easing the financial sting of coverage for cell and gene therapies, has ...
The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for ...
Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...
Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) mobilization predicting 16.9 million and 19.6 million cells/kg collected in a ...
Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...
Background CFTR modulators have transformed cystic fibrosis (CF) treatment, but individual responses vary even among patients with identical CFTR genotypes. This underscores the need for predictive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback